Abstract | INTRODUCTION: The landscape of antiepileptic drugs is constantly evolving with new compounds being released onto the market on a regular basis. Most new agents are, at least initially, approved for use as adjunctive treatment of localization-related ( focal) epilepsy, and only rarely are new medications released for other types of epilepsy. Though it has been in use in other countries, clobazam is now approved for use in the USA, and specifically in the treatment of Lennox-Gastaut syndrome, a type of (symptomatic or cryptogenic) generalized epilepsy. AREAS COVERED: EXPERT OPINION:
Clobazam offers a new treatment option for patients with refractory epilepsy. It has been found to be a safe, well-tolerated adjunctive antiepileptic medication that has had long-standing international experience in thousands of patients. It is unlikely that clobazam will change treatment strategies radically; nonetheless additional options are always welcome as individual patients can respond to different regimens. Physicians should be comfortable prescribing clobazam because it is a benzodiazepine and has been used extensively outside of the USA.
|
Authors | Melissa Giarratano, Katherine Standley, Selim R Benbadis |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 13
Issue 2
Pg. 227-33
(Feb 2012)
ISSN: 1744-7666 [Electronic] England |
PMID | 22242724
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticonvulsants
- Benzodiazepines
- Clobazam
|
Topics |
- Anticonvulsants
(pharmacokinetics, pharmacology, therapeutic use)
- Benzodiazepines
(pharmacokinetics, pharmacology, therapeutic use)
- Clobazam
- Epilepsy, Generalized
(drug therapy, metabolism)
- Humans
|